[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
    "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=249019c7483f542489ce553e6c1eca20ee438fa665712f9aba2b8ad37b838fa7",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747240620,
      "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
      "id": 134471222,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=249019c7483f542489ce553e6c1eca20ee438fa665712f9aba2b8ad37b838fa7"
    }
  },
  {
    "ts": null,
    "headline": "Are Investors Making a Big Mistake Dumping Shares of CRISPR Therapeutics?",
    "summary": "CRISPR Therapeutics has an approved gene-therapy treatment still in its early growth stages.  One of them is CRISPR Therapeutics (NASDAQ: CRSP).  Its financials haven't been looking all that impressive and as a result, growth investors have been dumping the stock.",
    "url": "https://finnhub.io/api/news?id=b433c142b8f89973b978d6f70d50c41dfb8feaef478c0b95cb7c482cc0e76789",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747223100,
      "headline": "Are Investors Making a Big Mistake Dumping Shares of CRISPR Therapeutics?",
      "id": 134461073,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "CRISPR Therapeutics has an approved gene-therapy treatment still in its early growth stages.  One of them is CRISPR Therapeutics (NASDAQ: CRSP).  Its financials haven't been looking all that impressive and as a result, growth investors have been dumping the stock.",
      "url": "https://finnhub.io/api/news?id=b433c142b8f89973b978d6f70d50c41dfb8feaef478c0b95cb7c482cc0e76789"
    }
  },
  {
    "ts": null,
    "headline": "Verve Therapeutics Shares Rise After Narrower-Than-Expected 1Q Loss",
    "summary": "Verve Therapeutics Shares Rise After Narrower-Than-Expected 1Q Loss",
    "url": "https://finnhub.io/api/news?id=fc4f748ef7c7355d6e48fd8d09dd8f6abce23214d1e4dbe143e2cf94f51ab225",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747221600,
      "headline": "Verve Therapeutics Shares Rise After Narrower-Than-Expected 1Q Loss",
      "id": 134440772,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Verve Therapeutics Shares Rise After Narrower-Than-Expected 1Q Loss",
      "url": "https://finnhub.io/api/news?id=fc4f748ef7c7355d6e48fd8d09dd8f6abce23214d1e4dbe143e2cf94f51ab225"
    }
  },
  {
    "ts": null,
    "headline": "BBH: Fear Of Price Controls Is Not The Problem",
    "summary": "The VanEck Biotech ETF offers lower risk with established companies, but 23% of AUM in speculative stocks poses a risk. Check out why I rate BBH a sell.",
    "url": "https://finnhub.io/api/news?id=5b9b2ebe607eb4d37afae12d3df292c9ef9d6c96c54e06f280d50c128a84afe4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747213200,
      "headline": "BBH: Fear Of Price Controls Is Not The Problem",
      "id": 134435713,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2200850893/image_2200850893.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "The VanEck Biotech ETF offers lower risk with established companies, but 23% of AUM in speculative stocks poses a risk. Check out why I rate BBH a sell.",
      "url": "https://finnhub.io/api/news?id=5b9b2ebe607eb4d37afae12d3df292c9ef9d6c96c54e06f280d50c128a84afe4"
    }
  },
  {
    "ts": null,
    "headline": "Parnassus Growth Equity Fund Q1 2025 Commentary",
    "summary": "Parnassus Growth Equity Fund (Investor Shares) returned -8.59% (net of fees) for the quarter, faring better than the Russell 1000 Growth Indexâs -9.97%.",
    "url": "https://finnhub.io/api/news?id=18c9bbc6b81692bfba93830d77b86454e725fe7091cfd4064d5b67663954fbde",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747212240,
      "headline": "Parnassus Growth Equity Fund Q1 2025 Commentary",
      "id": 134435565,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2166679764/image_2166679764.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Parnassus Growth Equity Fund (Investor Shares) returned -8.59% (net of fees) for the quarter, faring better than the Russell 1000 Growth Indexâs -9.97%.",
      "url": "https://finnhub.io/api/news?id=18c9bbc6b81692bfba93830d77b86454e725fe7091cfd4064d5b67663954fbde"
    }
  },
  {
    "ts": null,
    "headline": "Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses",
    "summary": "As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including United Therapeutics (NASDAQ:UTHR) and its peers.",
    "url": "https://finnhub.io/api/news?id=5d1b4933b8f2f350013fdcdf5234ad467178f93a9f926311b7b168c431989ec6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747193465,
      "headline": "Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses",
      "id": 134460789,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including United Therapeutics (NASDAQ:UTHR) and its peers.",
      "url": "https://finnhub.io/api/news?id=5d1b4933b8f2f350013fdcdf5234ad467178f93a9f926311b7b168c431989ec6"
    }
  }
]